Home › Companies › APGE

Apogee Therapeutics

APGE Acquired Rare disease Lead: Phase 2 3 Biotech Distilled articles ↓

Dermatology GI/Hepatology Respiratory Protein

Most recent annual filing: 2026-03-02

Pipeline (9 active programs)

zumilokibart

APG777

Protein Target: IL-13

Atopic Dermatitis Phase 2 subcutaneous NCT06395948
Asthma Phase 1 subcutaneous NCT06920901
Eosinophilic Esophagitis subcutaneous

APG990

Protein Target: OX40L

Atopic Dermatitis Phase 1 subcutaneous

APG279

Protein Target: IL-13, OX40L

Atopic Dermatitis Phase 1 subcutaneous

APG333

Protein Target: TSLP

Undisclosed indication Phase 1 subcutaneous

APG273

Protein Target: IL-13, TSLP

Asthma Preclinical subcutaneous
Chronic Obstructive Pulmonary Disease Preclinical subcutaneous

APG808

Protein Target: IL-4Rα

Asthma Phase 1 subcutaneous

Biotech Distilled coverage (3)

2026-06-22 UPDATE: Apogee Therapeutics (APGE) - The Takeout Lands at $135.11 🔒 Paid
2026-05-27 UPDATE: Apogee Therapeutics (APGE) - The Catalyst Lands, and the Stock Sells the News 🔒 Paid
2026-05-05 Apogee Therapeutics (APGE) - Scientific Deep Dive for ZUMILOKIBART and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.